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Achievement of normoglycemia with exogenous insulin treat-
ment requires the use of high doses of hormone, which in-
creases the risk of life-threatening hypoglycemic episodes. We
developed a gene therapy approach to control diabetic hyper-
glycemia based on co-expression of the insulin and glucokinase
genes in skeletal muscle. Previous studies proved the feasibility
of gene delivery to large diabetic animals with adeno-associated
viral (AAV) vectors. Here, we report the long-term (8 years)
follow-up after a single administration of therapeutic vectors
to diabetic dogs. Successful, multi-year control of glycemia
was achieved without the need of supplementation with exoge-
nous insulin. Metabolic correction was demonstrated through
normalization of serum levels of fructosamine, triglycerides,
and cholesterol and remarkable improvement in the response
to an oral glucose challenge. The persistence of vector genomes
and therapeutic transgene expression years after vector delivery
was documented in multiple samples from treated muscles,
which showed normal morphology. Thus, this study demon-
strates the long-term efﬁcacy and safety of insulin and glucoki-
nase gene transfer in large animals and especially the ability of
the system to respond to the changes in metabolic needs as
animals grow older.
INTRODUCTION
The ﬁeld of gene therapy has recently seen the realization of its full
potential, with many clinical studies providing unquestionable evi-
dence of efﬁcacy and safety for a variety of diseases.1 Indeed, in
2012, Glybera by UniQure, a muscle-directed, adeno-associated
viral (AAV) vector-based gene therapy for the treatment of lipopro-
tein lipase deﬁciency, became the ﬁrst gene therapy product of the
western world to gain market approval in Europe.2,3 Having over-
come many of the challenges that hampered the success of gene
therapy in the initial years, the technology has broadened its
range of potential applications from monogenic to non-hereditary,Molecular Therapy: Methods & C
This is an open access article under the CC BY-Ncomplex diseases, such as cancer, cardiovascular disease, and
diabetes.1,4–6
AAV vectors can be used to engineer the skeletal muscle through sin-
gle intramuscular administrations to lower diabetic hyperglycemia.7,8
Using AAVs of serotype 1 (AAV1) encoding the insulin (Ins) and
glucokinase (Gck) genes, we have shown long-term control of hyper-
glycemia and prevention of secondary complications in mice with
streptozotocin-induced diabetes.7 Furthermore, treatment of dogs
with experimental diabetes has demonstrated feasibility of Ins+Gck
gene therapy in large animals.8 Conceptually, our approach is based
on the co-expression of basal and low levels of Ins and the glucose-
phosphorylating enzyme Gck.7,9–11 When overt hyperglycemia is
established in a situation of absolute Ins deﬁciency, translocation of
glucose transporter type 4 (GLUT-4) to the plasma membrane and
the mRNA levels and activity of HKII, the enzyme that phosphory-
lates glucose upon entry to the cell, are decreased in muscle cells,12,13
compromising the ability of skeletal muscle to dispose of glucose after
a meal. In contrast to HKII, hepatic Gck has a high KM for glucose
(about 8 mM), is not inhibited by glucose 6-phosphate, and shows
kinetic cooperativity with glucose.14 Therefore, glucose uptake can
be enhanced in diabetic muscles in a glucose-dependent manner
through co-expression of constant, low levels of Ins that ensure
translocation of GLUT-4 and of Gck, which draws glucose uptake
into engineered muscle cells. The combination of these two genes
thus generates a “glucose sensor” in skeletal muscle that uptakes
large quantities of glucose only when circulating glucose levels
rise, such as in postprandial conditions, but does not cause hypogly-
cemia because Gck activity is shut down at physiological glucose
concentrations.linical Development Vol. 6 September 2017 ª 2017 The Authors. 1
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Figure 1. Correction of Diabetes for 8 Years in Dogs that Received a Single Treatment with AAV1-Ins+Gck Gene Therapy
(A and B) Follow-up of glycemia, body weight, and insulinemia in diabetic dogs 1 and 2 treated with AAV1-Ins and AAV1-Gck vectors at 1 1012 vg/kg each. Figures depict
the results of the monitoring from years 4 to 8 after gene transfer. “Time 0” indicates the moment of diabetes induction.8 Red arrows indicate the moment of AAV
administration. Gray bars indicate the range of fasting normoglycemia in dogs.20 Insulinemia remained within the range of fasted healthy animals (dashed lines) in both AAV1-
treated diabetic dogs for the whole of the follow-up period. (C) Quantification of the b cell area in pancreas samples (four sections of two to four different pancreatic regions)
from a healthy dog and dogs 1 and 2 obtained at the end of the study. Diabetes induction led to >95% reduction in b cell area per pancreas area in both dogs. (D) Serum levels
of human C-peptide in healthy (H) dogs and in dogs 1 and 2. Each bar represents the mean ± SEM of six measurements performed from year 4 to year 8 after treatment. The
detection of human C-peptide in AAV1-Ins+Gck-treated dogs demonstrated that proinsulin was produced and processed in the engineered skeletal muscle.
Molecular Therapy: Methods & Clinical DevelopmentTranslational efforts require the evaluation of the long-term efﬁcacy
and safety of Ins+Gck gene transfer in large animals and especially
the ability of the system to respond to the changes in metabolic needs
as animals grow older. Here, we report the results of the long-term (up
to 8 years) follow-up of diabetic dogs treated with a single intramus-
cular administration of AAV1-Ins and AAV1-Gck.8
RESULTS
Glycemic Control in Treated Dogs
We previously demonstrated that diabetes could be treated in dogs
with Ins+Gck gene therapy.8 Two of the treated dogs have now
been followed for up to 8 years to assess long-term efﬁcacy and safety.
Despite aging, fasting normoglycemia was maintained in both dogs2 Molecular Therapy: Methods & Clinical Development Vol. 6 Septembeduring the whole observational period (Figures 1A and 1B). Dogs
gained weight as expected for healthy dogs (Figures 1A and 1B)
and survived until the day of sacriﬁce without the need of exogenous
Ins therapy. Circulating Ins levels were very similar in both dogs and
remained within the range observed in healthy fasted dogs at all time
points analyzed, demonstrating production of the therapeutic protein
at constant low levels for 8 years (Figures 1A and 1B). The quanti-
ﬁcation of remaining pancreatic b cells demonstrated the absence
of canine Ins-producing cells in the pancreas of dogs 1 and 2 after
8 years of diabetes (Figure 1C). The presence of human C-peptide
in the serum of both AAV1-treated dogs (Figure 1D) further
conﬁrmed that circulating Ins derived from the production and secre-
tion of human Ins from AAV1-injected muscles.r 2017
Figure 2. Normalization of Metabolic Parameters
following AAV1-Ins+Gck Treatment
(A) Follow-up of serum fructosamine levels in dogs 1 and 2.
Each bar represents the mean ± SEM of 5–12 de-
terminations performed in a given year posttreatment. The
average fructosamine value measured in four age-
matched healthy (H) dogs (8–11 years of age) is provided
as a reference. The dashed line indicates the limit of what is
considered good glycemic control in veterinary medi-
cine.20 Fructosamine levels between 350 and 400 mmol/L
indicate excellent glycemic control, between 400 and
450 mmol/L good glycemic control, and between 450
and 500 mmol/L fair glycemic control; concentrations
>500 mmol/L indicate poor glycemic control.20 (B) OGTT
performed at a dose of glucose of 1.75 g/kg in 12 hr fasted
dogs. After the load, glycemia declined to less than
200 mg/dL before 2 hr in both Ins+Gck-treated dogs,
i.e., below the threshold for diabetes diagnosis according
to American Diabetes Association guidelines (2-hr plasma
glucose <200 mg/dL). Data represent the OGTT per-
formed 1 month before sacrifice, i.e., 8 years after
treatment. The average OGTT curve for six untreated
diabetic dogs (solid squares) and four age-matched
healthy dogs (empty circles) are provided as a reference.
(C and D) Follow-up of serum triglycerides (C) and choles-
terol (D) in AAV1-Ins+Gck-treated dogs. Throughout the
years, values remained within the normal range (gray)18 in
both animals. (E) Preservation of the integrity of the skeletal
muscle after AAV1-Ins+Gck gene transfer. The histopath-
ological analysis of the quadriceps (dog 1) and tibialis
cranialis (dog 2) was performed on samples obtained at
necropsy. No signs of muscle pathology or inflammation
were observed by H&E staining. No sign of pathological
glycogen storage was documented after periodic acid-
Schiff (PAS) staining. Representative images obtained from
a healthy control (Con) dog are provided as a reference.
Original magnification 200.
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During the whole follow-up period, serum fructosamine levels ranged
from 240 to 350 mmol/L in both AAV1-treated dogs (Figure 2A).
These values were below the upper limit of what is considered good
glycemic control in veterinary medicine (450 mmol/L),15 a control
generally hard to achieve even through multiple daily administrations
of exogenous Ins.8,15,16 In response to an oral glucose load, Ins+Gck-
treated dogs showed only a slight increase in blood glucose
levels compared with those documented in healthy age-matched
controls, quickly returning to normoglycemic values (Figure 2B).
Moreover, 2 hr after the load, the glycemia of both treated dogs was
less than 200 mg/dL, a response considered non-diabetic by the
American Diabetes Association guidelines.17 Serum triglyceride and
total cholesterol levels also remained within the range observed inMolecular Therapy: Methods &healthy dogs18 (Figures 2C and 2D). On the
other hand, no signs of muscle pathology or
inﬂammation were observed in either animal,
and periodic acid-Schiff (PAS) staining demon-
strated that treated muscles did not accumulatepathological amounts of glycogen as the results of the therapy
(Figure 2E).
Vector Biodistribution and Persistent Expression of Therapeutic
Genes
At sacriﬁce, multiple samples from the quadriceps femoris and tibialis
cranialis muscles, the latter equivalent to human tibialis anterior, as
well as liver from both AAV-injected dogs were obtained. In dog 1,
88% and 82% of the samples tested positive for AAV1-Ins and
AAV1-Gck vector genomes, respectively (Figure 3A). The percent-
ages were slightly lower for dog 2, in which 63% of the muscle samples
had detectable AAV1-Ins and AAV1-Gck vector genomes (Fig-
ure 3B). In contrast, no vector genomes were detected in the liver
of any of the animals with either Ins- or Gck-speciﬁc primers orClinical Development Vol. 6 September 2017 3
Figure 3. Viral Vector Biodistribution
(A and B) Quantification of AAV1-Ins (top panels) and
AAV1-Gck (bottom panels) vector genome (vg) copy
numbers, expressed as vg per cell (vg/cell), in samples of
liver (L), quadriceps (Q), and tibialis cranialis (T) from dogs 1
(A) and 2 (B) obtained at necropsy. No vg were detected in
any of the liver samples from either animal. ND, non-
detectable.
Molecular Therapy: Methods & Clinical Developmentprobes (Figures 3A and 3B). In agreement with the vector genome
data, we detected Ins and Gck mRNA in most of the quadriceps fem-
oris and tibialis cranialis samples from dogs 1 and 2, but not in the
liver (Figures 4A and 4B). Furthermore, we documented Gck activity
in multiple samples from the quadriceps femoris and tibialis cranialis
muscles from both dogs (Figure 4C). Overall, these results provide
strong evidence of the persistence of vector genomes in injected
dog muscles, which mediate long-term expression of therapeutic pro-
teins for8 years after a single vector administration and explain the
tight control of glycemia achieved in these animals for such a long
period of time.
DISCUSSION
The goals of any therapy for Ins-deﬁcient diabetes are to attain nor-
moglycemia and avoid hypoglycemia. With conventional replace-
ment therapy, the ﬁrst aim requires the use of high doses of Ins, which
increases the likelihood of hypoglycemic episodes (The United
Kingdom Prospective Diabetes Study [UKPDS]).19 Also, to achieve
optimal control, any approach should be able to rapidly respond to
changes in blood sugar, such as those associated with food intake,
exercise, or stress, with minimal intervention from the patient.
Here, we report the successful control of diabetic hyperglycemia after
a single delivery of the human Ins and rat Gck genes to the muscle of
dogs, with therapeutic efﬁcacy demonstrated for a period that essen-
tially covered the lifetime of the animals.
The normalization of biochemical parameters in the two dogs
monitored for 8 years provides strong evidence of the long-lasting
control of glycemia achieved following gene transfer of the Ins and
Gck genes. It is worth noticing that the oral glucose tolerance
test (OGTT) was performed in elderly animals (9 years old) and
8 years after a single dosing of the gene therapy treatment, indi-
cating that the capacity of treated muscles to dispose of glucose after
a challenge persisted through the years. Further evidence of efﬁcacy
was provided by the fact that Ins+Gck-treated dogs showed fructos-4 Molecular Therapy: Methods & Clinical Development Vol. 6 September 2017amine levels below what is considered to reﬂect
excellent glycemic control in veterinary medi-
cine.20 Fructosamine, which measures average
glucose levels over approximately 2–3 weeks,
is used in veterinary medicine to monitor treat-
ment efﬁcacy in a similar way to hemoglobin
A1c in humans.20 Further, this was consistent
with the observation that gene therapy delayed
cataract development in dogs 1 and 2. In dia-betic dogs that received Ins+Gck, gene therapy cataracts were
evident at 8 and 9 years of age, i.e., several years after diabetes induc-
tion and similar to the age of development of cataracts in healthy
Beagle dogs. Indeed, 9 out of 13 age-matched healthy Beagle dogs
housed in the same facility as our Ins+Gck-treated dogs also had
cataracts. In contrast, a quick cataract development is observed in
diabetic dogs treated with exogenous Ins, of whom 80% develop
cataracts within 16 months of diagnosis.21 In our hands, diabetic
dogs of the same breed and housed in the same animal facility as
dogs 1 and 2, but treated with recombinant human Ins, developed
cataracts 3–9 months after diabetes induction.8 Also, throughout
the 8-year follow-up period, treated dogs showed normal circulating
levels of cholesterol and triglycerides. Hypercholesterolemia and
hypertriglyceridemia, together with hyperglycemia, constitute main
risk factors for cardiac disease in diabetic patients.22,23 Diabetic
dogs do not frequently develop long-term complications of dia-
betes.20 The only two common ﬁndings in clinical veterinary
medicine are the development of cataracts and urinary tract infec-
tions.8,20 Other long-term complications of diabetes such as ne-
phropathy, neuropathy, retinopathy, or cardiac disease are very
uncommon in diabetic dogs. This fact and the reduced number of
animals included in this long-term follow-up study preclude us
from drawing any strong conclusions on the efﬁcacy of our treat-
ment in preventing the development of secondary complications
of the disease.
Some of the previous gene therapy approaches developed to coun-
teract diabetic hyperglycemia relied on the glucose-regulated expres-
sion of Ins in surrogate non-b cells to respond to the changes in blood
glucose.24–30 Both naturally occurring and engineered hybrid pro-
moters have been used to achieve glucose-responsive expression of
Ins following in vivo delivery of gene transfer vectors.24–30 None of
these systems, however, has managed to mimic the quick response
to glucose of the Ins promoter,31 and the slow transcriptional activa-
tion of these promoters may result in an inadequate Ins secretory
Figure 4. Long-Lasting Therapeutic Gene Expression
following AAV-Mediated Gene Transfer to the
Muscle of Dogs
(A and B) Expression of human Ins (top panels) and rat Gck
(bottom panels) in the liver (L), quadriceps (Q), and tibialis
cranialis (T) muscles from dogs 1 (A) and 2 (B). Human Ins
and rat Gck were not expressed in any of several liver
samples. a.u., arbitrary units. (C) Detection of Gck activity
in quadriceps and tibialis cranialis muscles from dogs 1
and 2 detected8 years after a single administration of the
gene therapy vectors. ND, non-detectable.
www.moleculartherapy.orgresponse, with postprandial episodes of hyperglycemia followed by
hypoglycemia several hours later.
In our system, the enzyme Gck, and not Ins, is the component that
responds to glucose levels by activating glucose phosphorylation
when intracellular levels of glucose are high. In engineered muscle
cells, the activation of the Ins signaling is required to ensure sufﬁcient
translocation of the GLUT-4 transporter to the plasma membrane, so
that glucose transport does not become a rate-limiting step to the sys-
tem. Glucose uptake is then driven by the quick phosphorylation of
large amounts of glucose by the enzyme Gck, active while glucose
levels are high and inoperative when they are normal. Thus, despite
the constitutive expression of Ins, the system does respond to glucose
levels, andmuscle glucose uptake is stimulated in conditions of hyper-
glycemia, such as in postprandial conditions, but is progressively shut
down as glycemia returns to physiological levels. The good response
of the system to glucose levels was evidenced by the OGTT. The peak
glucose level reached in the Ins+Gck-treated dogs was substantially
lower than in untreated diabetic animals, albeit slightly higher than
in age-matched healthy dogs, but glycemia returned to normal
values fairly quickly in the Ins+Gck-treated dogs and was less than
200 mg/dL 2 hr after the load, a proﬁle considered non-diabetic ac-
cording to American Diabetes Association guidelines.17 The fact
that only very low, constant levels of Ins are required to maintain nor-
moglycemia even after a glucose challenge increases the safety proﬁle
of our proposed therapy and constitutes an advantage over the use ofMolecular Therapy: Methods &glucose-regulated promoters with slow kinetics
of response. We previously reported that
younger Ins+Gck-treated dogs did not develop
hypoglycemia even when subjected to intense ex-
ercise after 24 hr of fasting.8 In this longer
follow-up we did not observe hypoglycemia as
animals grew older and their metabolic needs
changed, demonstrating that the risk of hypogly-
cemia of our approach is very low. Furthermore,
the production of low, constant levels of Ins has
additional beneﬁcial effects on metabolism. We
have observed in mice and dogs that the low
levels of Ins produced by engineered muscles
are sufﬁcient to suppress hepatic glucose produc-
tion, lipolysis, and ketoacidosis.7,8 Indeed, dia-betic animals of both species gained weight with age and had normal
fat content after Ins+Gck gene therapy.7,8
This report contains the longest efﬁcacy data after gene transfer in a
large-animal model of a non-monogenic metabolic disease. Indeed,
the longest lasting efﬁcacy for an experimental therapy for diabetes
described so far was obtained following transplantation of porcine
islets to dogs and non-human primates, in which 1.8 and 1.7 years
of good glycemic control were reported, respectively.32,33 For clinical
translation, the approach requires further development. In this re-
gard, the generation of single AAV vectors that encode both genes
is under way. This will, in theory, improve gene transfer efﬁciency
because the likelihood of getting both genes in a given cell will in-
crease, allow the use of lower vector doses, minimizing potential
toxicity and easing the manufacturing burden, and simplify the regu-
latory pathway. Toward a future application in humans, this study
demonstrates in large animals the long-term efﬁcacy and safety of
Ins and Gck gene transfer, and especially the adaptability of the sys-
tem to the changes in metabolic needs associated with aging. We
believe gene therapy holds great potential for the treatment of dia-
betes in humans.
MATERIALS AND METHODS
Animals
Male Beagle dogs were purchased from Isoquimen and housed at
the Servei de Granges i Camps Experimentals of the UniversitatClinical Development Vol. 6 September 2017 5
Molecular Therapy: Methods & Clinical DevelopmentAutònoma de Barcelona (UAB). Animals were fed individually once
daily at 9:00 a.m. with 30 g/kg body weight standard dry food (Nestle).
Experimental diabetes was induced as previously described.8 Dogs
were monitored regularly at the UAB Veterinary Clinical Hospital
and sacriﬁced by administration of a lethal dose of pentobarbital.
All experimental procedures were approved by the Ethics Committee
for Animal and Human Experimentation of UAB.
AAV Production and Administration
AAV1 vectors driving the expression of human Ins containing a furin
endoprotease cleavage signal and rat Gck were produced and deliv-
ered to dogs 1 and 2 at a dose of 1  1012 vector genomes (vg)/kg
of each vector, as previously described.8
Vector Biodistribution
Tissues were digested overnight in Proteinase K (0.2 mg/mL). Total
DNA was isolated with the MasterPureDNA Puriﬁcation Kit
(Epicenter Biotechnologies). Vg copy number was determined in
20 ng of genomic DNA by TaqMan qPCR with primers and probes
speciﬁc for hINS and rGck: hINS forward primer: 50-GTC CTG
GGT GTG TAG AAG AAG-30; hINS reverse primer: 50-CTT TGT
GAA CCA ACA CCT GTG-30; hINS probe: 50-TCG TTC CCC
GCA CAC TAG GTA GA-30; rGck forward primer: 50-TGT CAA
GGA AGT CAG AGA TGC-30; rGck reverse primer: 50-ATG CTG
GTC AAA GTG GGA G-30; rGck probe: 50-AGG GCA GTG GAG
CGT GAAGAC-30. Vg per sample were interpolated from a standard
curve built by serial dilutions of linearized plasmids bearing the target
sequence spiked into 20 ng of non-transduced genomic DNA.
Transgene Expression
Total RNA was extracted from different tissues using Tripure isola-
tion reagent (Roche Molecular Biochemicals) and the RNeasy Mini
Kit (QIAGEN). Total RNA (1 mg) was retrotranscribed using the
Transcriptor First Strand cDNA Synthesis Kit (Roche). Quantitative
real-time (RT)-qPCR was performed in a LightCycler 480 II (Roche)
using LightCycler 480 probes Master (Roche). Transgene-speciﬁc
primers and probes were the same as for biodistribution studies. Re-
sults were normalized by Rplp0 expression using primers and probe
speciﬁc for dogRplp0: forward primer: 50-ACC TCT TTC TTC
CAG GCT TTA G-30; reverse primer: 50-CCA CTT TGT CTC
CCG TCT TAA T-30; probe: 50-ACC ATT GAA ATC TTG AGT
GAT GTG CAG C-30.
Morphological and Immunohistochemical Analysis
Samples were ﬁxed in 10% formalin, embedded in parafﬁn, and
sectioned. b cell area was measured on multiple sections covering
the whole pancreas.8 To analyze muscle integrity, we stained muscle
cross sections with H&E (Dako). PAS staining (Sigma-Aldrich) was
used to evaluate muscle glycogen content.
Hormone, Metabolites, and Gck Activity
Human Ins and human C-peptide were measured in serum samples
by radioimmunoassay.8 Blood glucose levels were determined using
a Glucometer Elite analyzer (Bayer). Serum fructosamine, triglycer-6 Molecular Therapy: Methods & Clinical Development Vol. 6 Septembeides, and cholesterol were measured by spectrophotometry.8,34 Gck
activity was measured in extracts from frozen muscle samples.8
OGTT
OGTTs were performed on 12 hr fasted dogs that received a 1.75 g/kg
body weight gavage of glucose.8
Statistical Analysis
All values are expressed as means ± SEM.
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